--- title: "Sciwind secures China’s NMPA approval for Ecnoglutide injection" type: "News" locale: "en" url: "https://longbridge.com/en/news/278383893.md" description: "Sciwind has received approval from China's NMPA for Ecnoglutide injection, a GLP-1 receptor agonist aimed at chronic weight management in adults with obesity. The approval follows a Phase III clinical trial published in The Lancet, showing significant weight loss and improvements in cardiometabolic risk factors. Ecnoglutide demonstrated a mean weight reduction of 15.4% at the highest dose, with 92.8% of participants losing at least 5%. Sciwind's CEO highlighted this as a milestone for innovative drugs in the GLP-1 field." datetime: "2026-03-09T10:42:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278383893.md) - [en](https://longbridge.com/en/news/278383893.md) - [zh-HK](https://longbridge.com/zh-HK/news/278383893.md) --- # Sciwind secures China’s NMPA approval for Ecnoglutide injection The trial demonstrated dose-dependent results at week 48, with patients on 2.4mg achieving a 15.4% weight reduction. Credit: GBALLGIGGSPHOTO / Shutterstock.com. Sciwind Biosciences has received China’s National Medical Products Administration (NMPA) approval for its Ecnoglutide injection for chronic weight management. Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight. ### Go deeper with GlobalData - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### LOA and PTSR Model - Ecnoglutide in Obesity - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### LOA and PTSR Model - Ecnoglutide in Type 2 Diabetes ##### Go deeper with GlobalData The gold standard of business intelligence. Find out more #### Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more It is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment. This mechanism enables potent and sustained weight loss while supporting metabolic improvements and minimising the risk of chronic diseases. Ecnoglutide’s approval was based on a Phase III clinical trial that was published in _The Lancet Diabetes & Endocrinology_ in June 2025. The trial demonstrated dose-dependent results at week 48, where patients receiving the highest dose (2.4mg) achieved a mean 15.4% (placebo-adjusted 15.1%) reduction in weight. Furthermore, 92.8% of participants realised a weight loss of at least 5%, with many surpassing 10% or 15% reductions. Weight loss continued throughout 48 weeks without plateauing. GlobalData Strategic Intelligence # US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Participants receiving Ecnoglutide also saw significant improvements across cardiometabolic risk factors such as blood pressure, fasting glucose, insulin levels, haemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile, and waist circumference. The treatment led to a notable decrease in uric acid levels, up to 54.3µmol/L, and reduced hyperuricaemia incidence. For those with baseline liver fat content of 8% or above, Ecnoglutide resulted in a mean reduction of -53.1% by week 40 among those on the 2.4mg dose. Liver enzyme concentrations also dropped more than those recorded in the placebo group. Sciwind Biosciences founder and CEO Dr Hai Pan said: “The approval of Ecnoglutide injection for weight management is an important milestone for Sciwind in the metabolic disease area, and a breakthrough for China’s innovative drugs in the global GLP-1 field. “As the world’s first approved cAMP-biased GLP-1 receptor agonist, Ecnoglutide injection has now completed its strategic positioning for both weight management and type 2 diabetes indications.” ### Related Stocks - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [588780.CN](https://longbridge.com/en/quote/588780.CN.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) ## Related News & Research - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)